Three independent discounted-cash-flow-style models value Cullinan Therapeutics, Inc. Common Stock every trading day. 0 of 3 currently price CGEM above its market price.
| Free Cash Flow model | $-632.15 |
| Excess Profit model | $-495.11 |
| Residual Earnings model | $-0.18 |
| Dividend Discount model | — |
| Piotroski F-Score | 3 / 9 |
| Return on invested capital | +21.2% |
| Net debt / EBITDA | -0.6× |
| Gross margin | +100.0% |
| Revenue CAGR | +1361.1% |
| Cash conversion | -1.2× |
| Dividend yield | — |
| Buyback yield | — |
These are StockKitty's default assumptions. In the app, the models recompute live as you adjust growth, discount rates, and margins — and the AI explains the bull case, bear case, and quality picture.
Open CGEM in StockKitty